Physician profile
Nefertiti C Dupont
NPI 1326105511
$35,980.68
in general payments reported to CMS, 2019-2025
14 companies · $14K in 2025
The $14K reported for 2025 was more than what 93% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,795 · 2020: $2,498 · 2021: $134 · 2022: $337 · 2024: $14K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,200 · Travel and Lodging: $613 · Food and Beverage: $429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,975.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,200.00 |
| Travel and Lodging | $612.89 |
| Food and Beverage | $429.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanara Medtech INC. | $28,262.18 | 2020-2025 | Celleraterx, Celleraterx |
| Wound Management Technologies, INC | $4,134.60 | 2019 | |
| Glaxosmithkline, LLC. | $2,075.25 | 2020 | |
| Merck Sharp & Dohme LLC | $412.03 | 2019-2024 | Lynparza, Keytruda |
| Mckesson Medical-Surgical, INC. | $275.00 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $180.49 | 2021-2025 | Lynparza |
| Tesaro, INC. | $139.20 | 2019 | |
| Clovis Oncology, INC. | $124.56 | 2019 | |
| Coopersurgical, INC. | $111.50 | 2019 | |
| Myriad Genetic Laboratories, INC. | $94.17 | 2022-2024 | Myrisk |
| Tempus Ai, INC | $71.73 | 2025 | Xt Cdx |
| Abbvie INC. | $46.10 | 2025 | |
| Ethicon US, LLC | $31.42 | 2025 | Vistaseal, Evarrest |
| Eisai INC. | $22.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nefertiti Dupont listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.